AstraZeneca plc is investing $1.5 billion to build a new Antibody-Drug Conjugates (ADCs) manufacturing facility in Singapore by 2029.

This will be AstraZeneca's first facility to manage the entire manufacturing process for ADCs, which target and kill cancer cells.

The investment supports AstraZeneca's strategy to strengthen its global supply chain, following recent expansions in various markets.

The Singaporean government's economic development board is backing the project, indicating strong local support.

CEO Pascal Soriot highlights the potential of ADCs to transform cancer treatment, possibly replacing traditional chemotherapy.